Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00862745 · ClinicalTrials.gov registry record · Phase 4
Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 645
- Enrollment target
NCT00862745 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 645 participants.
The verdict
NCT00862745, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 645 participants
- Enrollment target
Study Summary
Six hundred and thirty-six women diagnosed with urge urinary incontinence (UUI) by a three-item self-administered questionnaire (3IQ) will be randomized to 12 weeks of fesoterodine or matching placebo. The study will take place at up to 14 clinical sites in the US. All participants who complete the 12-week randomized trial will be offered open-label fesoterodine for an additional 9 months. The hypothesis of the randomized controlled trial is that among women diagnosed with urge incontinence using the 3IQ, fesoterodine is more effective than placebo in reducing the mean number of urge incontinence episodes per day.
Interventions
- DRUG Matching Placebo
- DRUG Fesoterodine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 645 participants |
| Start Date | 2009-01 |
| Est. Completion | 2011-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00862745
The ClinicalTrials.gov registry entry for NCT00862745 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 645 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT00862745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00862745 about?
NCT00862745 is a clinical study titled "Bringing Simple Urge Incontinence Diagnosis & Treatment to Providers (BRIDGES)". Six hundred and thirty-six women diagnosed with urge urinary incontinence (UUI) by a three-item self-administered questionnaire (3IQ) will be randomized to 12 weeks of fesoterodine or matching placebo. The study will take place at up to 14 clinical sites in the US. All participants who complete the ...
What is the current status of trial NCT00862745?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 645 participants. The study started on 2009-01. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00862745?
The interventions under investigation include: Matching Placebo (DRUG), Fesoterodine (DRUG).
Who is sponsoring clinical trial NCT00862745?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.